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Aim of the database: The main purpose of the database of the Danish Renal Cancer Group 
(DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily 
to conduct observational research.
Study population: DaRenCaData includes all Danish patients with a first-time diagnosis of 
renal cancer in the Danish National Pathology Registry since August 1, 2010.
Main variables: DaRenCaData holds data on demographic characteristics, treatments, and 
pathology collected through linkage to central registries and online registration of a few  clinical 
key variables. Eight quality indicators have been selected for monitoring treatment quality and 
outcome after renal cancer.
Descriptive data: The incidence of renal cancer in Denmark has increased from 12.7 per 
100,000 population-years in 2010–2011 to 15.9 per 100,000 population-years in 2014–2015. 
A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the 
period August 1, 2010–July 31, 2015. The completeness of data registration has increased 
substantially since the first years of the database. A tendency toward smaller and less advanced 
tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative 
morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and 
was 84.1% in 2014–2015.
Conclusion: DaRenCaData provides valuable information on quality of and outcome after renal 
cancer treatment. Efforts to improve collection and registration of data are ongoing.
Keywords: kidney cancer, database, clinical quality, indicators, incidence, survival, observa-
tional research
Background
Renal cancer accounts for 3%–4% of new cancer cases in adults.1–3 Data from the 
Nordic cancer registry NORDCAN show that renal cancer in Denmark in the years 
2009–2013 comprised 2.5% of all new male and 1.4% of all new female cancer cases.3 
Survival after renal cancer has been lower in Denmark compared to the other Nordic 
countries for decades.3,4
The multidisciplinary Danish Renal Cancer Group (DaRenCa) was established in 
2006 following a national plan to improve survival of cancer for all Danish patients.5 
DaRenCa is a group of academic experts representing urology, oncology, pathology, 
radiology, nuclear medicine, and epidemiology dealing with cancer originating from 
the renal parenchyma. The aim of DaRenCa is to improve the renal cancer survival 
in Denmark, and the group is responsible for developing national guidelines for 
diagnosis and treatment of renal cancer. The nationwide database of the DaRenCa 
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(DaRenCaData) was established in 2010 as one of the other 
tasks of the group.
Aim of the database
The main purpose of the database is to improve the clinical 
quality of renal cancer treatment in Denmark by monitoring 
selected processes and outcome after renal cancer treatment 
and secondarily to provide an important data source for 
observational research.
Study population
DaRenCaData includes all patients with a first-time diagnosis 
of renal cancer in Denmark since August 1, 2010. The patients 
are identified by the first-time registration of a diagnosis of 
renal cancer in the Danish National Pathology Registry to 
secure verification by histology or cytology.6 Through the 
Danish National Patient Registry, the database additionally 
identifies all surgical treatment procedures performed on 
patients with renal cancer.7
Main variables
The variables in the database are obtained from two main 
sources: through data linkage from central national registries 
and through data registered online in a web-based form by 
the treating clinicians. This online registration form is part 
of a common platform for the five urooncological databases 
in Denmark.8
Information on sex, age, and vital status is retrieved from 
the Danish National Civil Registry.9
Data on specific surgical and oncological treatment as 
well as comorbidity are retrieved from the National Patient 
 Registry.7 These data are part of the routine registration done 
in connection with procedures performed during hospital-
ization and outpatient treatment at hospitals. The surgical 
procedures are registered as radical or partial nephrectomies 
or ablative procedures (cryotherapy and radio frequency 
ablation), and whether the procedures are performed laparo-
scopically or open. Variables describing the surgical quality 
include information on the length of hospital stay, 30-day 
postoperative mortality, and 30-day postoperative morbidity. 
Information on specific oncological treatment modalities is 
also retrieved.
Systematized Nomenclature of Medicine codes for the 
histological subtype of cancer, Fuhrman grade, Leibovich 
score, pT-stage, and type of specimen are drawn from the 
Danish National Pathology Registry.6
Additional data from the web-based form include: civil 
registration number as patient identifier, date of diagnosis, 
main debut symptoms (incidentally found tumor, hematuria, 
nonspecific symptoms), and results of blood tests performed 
at the time of diagnosis (hemoglobin, C-reactive protein, 
ionized calcium, lactate dehydrogenase, serum sodium, 
neutrophils). The database is not collecting data on lifestyle 
factors. In case of locoregional or metastatic recurrent dis-
ease, a special recurrence form is used.
Eight quality indicators with recommended standards 
based on experience and available literature have been 
selected for monitoring the clinical quality of renal cancer 
treatment in Denmark. These indicators collected once a 
year include description of the treatment of renal cancer 
(process indicators) as well as description of outcome (result 
indicators).
Data quality
As most data come from preexisting registries and only a 
few data are registered manually in the web-based forms, it 
should be possible to achieve a high completeness of data, 
obviously depending on the quality of these data.
All urological, surgical, oncological, and other depart-
ments diagnosing and treating patients with renal cancer 
register online in the web-based form at the time of diagnosis. 
This form was filled in for 89.0% of all new renal cancer 
cases during the last study period August 1, 2014–July 31, 
2015, with a variation between departments treating more 
than ten patients between 37.5% and 98.6%. This registration 
has improved over the years: 65.4% in 2010–2011, 69.3% in 
2011–2012, 82.3% in 2012–2013, and 84.4% in 2013–2014. 
Ten urological departments diagnosed more than ten new 
patients with kidney cancer in 2014–2015. Four of these had a 
high and stable registration rate during all 5 years with a mean 
between 88.0% and 95.9%. Five improved their registration 
substantially, one from 14.5% to 87.7% and another from 
52.9% to 95.0%. Only one department showed a decrease 
in registration from 76.2% to 37.5%.10
As DaRenCaData is a newly established database with 
only 5 years of data collection to date, results and data from 
the initial years should be interpreted with caution. During 
the recent years, the algorithms for identification of patients 
with incident renal cancer in the pathology registry have been 
optimized. As a result, the data completeness and validity 
have improved over time. In particular, the algorithms have 
been redefined, and data from five larger hospitals diagnos-
ing and treating patients with renal cancer have undergone 
a detailed validation of data concerning the surgical proce-
dures and pathological data. This validation revealed that the 
main  reason for incomplete data was incorrect or incomplete 
registration of some of the clinical and pathological data. 
Validation of data on oncological treatment is currently 
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ongoing. Further validation studies will ensure an even 
higher completeness and validity of all data in DaRenCaData 
in the future.
Main results
During the period August 1, 2010–July 31, 2015, 3,977 
patients with renal cancer have been enrolled in the 
 database.11 Over this period, incidence has increased in total 
Table 1 Characteristics of the patient population in DaRenCaData
Characteristics Year of diagnosis (August 1–July 31)
2010–2011 2011–2012 2012–2013 2013–2014 2014–2015
New cases 705 724 769 880 899
New cases per 100,000 citizens, n 12.7 13.0 13.7 15.6 15.9
women, n (%) 230 (32.6) 242 (33.4) 267 (34.7) 305 (34.7) 313 (34.8)
Men, n (%) 475 (67.4) 482 (66.6) 502 (65.3) 575 (65.3) 586 (65.2)
Age at diagnosis (years)
Median 65 64 66 67 67
25th percentile 57 56 58 57 57
75th percentile 72 71 73 73 74
Comorbidity at diagnosisa
Score 0, n (%) 354 (50.2) 394 (54.4) 412 (53.6) 463 (52.6) 487 (54.2)
Score 1–2, n (%) 242 (34.3) 218 (30.1) 242 (31.5) 278 (31.6) 277 (30.8)
Score 3+, n (%) 109 (15.5) 112 (15.5) 115 (15.0) 139 (15.8) 135 (15.0)
Year of surgery (August 1–July 31)
2010–2011 2011–2012 2012–2013 2013–2014 2014–2015
Surgical procedures, n 591 644 656 749 807
Median age at surgery 64 64 65 65 66
Notes: aGiven as Charlson comorbidity index score.14 Data from  DaRenCa, a subgroup of Dansk Urologisk Cancer Gruppe.11
Abbreviation: DaRenCaData, database of the Danish Renal Cancer Group.
Table 2 Quality indicators and indicator results in DaRenCaData
Indicator Standard (%) Type Result (%)
Year of diagnosis (August 1–July 31) 
2010–201110 2011–201211 2012–201311 2013–201411 2014–201511
1a  Proportion of localized disease  
(T1–2, N0/x, M0/x) at diagnosis
$65 Process 51.2 50.0 52.5 54.3 54.8
1b  Proportion of localized disease  
(T1a, N0/x, M0/x) at diagnosis
Not yet defined Process 20.0 21.0 23.7 29.8 27.6
2a  Proportion of radical nephrectomies 
for local disease (T1–2) performed 
laparoscopically
$85 Process 65.3 75.9 74.4 76.0 76.4
2b  Proportion of radical nephrectomies 
performed laparoscopically
$65 Process 60.0 62.2 64.9 68.2 66.4
3 30-day morbidity #5 Result 4.3 4.3 3.4 4.2 4.4
4 Recurrencea within 3 years #25 Result 28.9 29.2
5 30-day mortality #0.5 Result 0.7 1.6 0.5 0.7 0.4
6a 1-year observed survival $80 Result 81.3 81.9 83.4 84.1
6b 3-year observed survival Not yet defined Result 68.2 69.9
7  Hospital stay #3 days after an 
endoscopic or ablative procedure
$85 Result 68.1 70.9 75.2 75.3 80.1
8  Proportion of T1a tumor treated by 
radical nephrectomy
#10 Result 46.7 35.0 25.1 26.8 17.4
Note: aRecurrence: locoregional or metastatic recurrent disease. TNM, the TNM system for describing the anatomical extent of disease are based on T (the extent of the 
primary tumour); N, the absence or presence of regional lymph node metastasis; M, the absence or presence of distant metastasis.
Abbreviation: DaRenCaData, database of the Danish Renal Cancer Group.
number of new cases and number of new cases per 100,000 
citizens (Table 1).12
The eight quality indicators as well as results from 2010 
to 2015 are summarized in Table 2.10,11
There has been a tendency toward use of more minimal 
invasive procedures with lesser surgical traumas. The pro-
portion of radical nephrectomies performed  laparoscopically 
has increased from 60.0% in 2010–2011 to 66.4% in 
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2014–2015.11 The proportion of nephron-preserving 
procedures (partial nephrectomy and ablation) increased from 
22.9% in 2010–2011 to 43.5% in 2014–2015, and the propor-
tion of patients with T1a (#4 cm) cancers who underwent a 
radical nephrectomy decreased from 46.7% in 2010–2011 to 
17.4% in 2014–2015.11 The proportion of patients who were 
hospitalized for 3 days or less after an endoscopic or ablative 
procedure increased from 68.1% to 80.1% during the last 5 
years, while the postoperative morbidity and mortality was 
stable during the last 5 years.11
Tumor size at diagnosis tends to be smaller and less 
advanced in the most recent years. The number of radical 
and partial nephrectomies with pT1a tumors increased 
from 17.6% in 2011–2012 to 29.8% in 2014–2015, while 
the  number of patients with pT3–4 tumors decreased from 
45.0% in 2011–2012 to 29.8% in 2014–2015.11
Information on the specific histological subtype, which 
is an important prognostic factor and used for determining 
later treatment of metastatic disease, was recorded for 53% 
of the newly diagnosed patients in 2010–2011, 74.5% in 
2011–2012, 87.5% in 2012–2013, 83.8% in 2013–2014, and 
85.9% in 2014–2015.11
The 1-year observed survival after the diagnosis of renal 
cancer increased from 81.3% for patients diagnosed in 
2010–2011 to 84.1% in patients diagnosed in 2014–2015.11 
The 3-year observed survival was 68.2% for patients diag-
nosed in 2010–2011, and 69.9% for patients diagnosed in 
2011–2012.11
Follow-up
All patients enrolled in the database are followed until death 
or emigration with collection of data comprising surgical and 
medical oncological treatment as well as data on the date and 
type of recurrence.
Data suggested to be included during follow-up in the 
future are, among others, the development of a new primary 
renal cancer in the residual and/or contralateral kidney and 
development of renal insufficiency after renal surgery.
Research
No research projects have evolved until now, but in the 
coming years, the database will be provide the basis for and 
conduct several observational studies of Danish patients 
with renal cancer.
Administrative issues and funding
DaRenCaData is funded by the Danish Regions by the 
Danish Clinical Registries as one of more than 60 national 
clinical quality databases in Denmark.13 Epidemiological, 
statistical, and technical support is provided by two regional 
registry support centers in Denmark (The Registry Support 
Center of Epidemiology and Biostatistics [North] and The 
Registry Support Center of Clinical Quality and Health 
Informatics [West]). The database is headed by a steering 
group representing the specialties in DaRenCa supplied by 
biostatistics and quality improvement. An annual report is 
published each year covering the period from August 1of the 
first year to July 31 of the next year.11 The publication follows 
a national audit by the steering group of national-, regional-, 
and institutional-based results. After publication, the regions 
and departments perform a local audit of the results for their 
own organization.
Conclusion
DaRenCaData was established in 2010 to provide valid 
information on renal cancer statistics.
Data from the first 5 years of the database suggest an 
improvement of survival, a tendency toward smaller and less 
advanced tumors at the time of diagnosis, and an increased 
use of less invasive surgery.
It is important to note that the database is relatively 
young, and the data from the first years should be interpreted 
with caution. Nevertheless, the completeness of the online 
registration has improved substantially during these first 5 
years. Effort to improve data completeness and validity is 
ongoing.
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